Onconova Therapeutics (NASDAQ: ONTX) was devalued by  Zacks Research  from a “purchase” rating to a “hold” rating in a research note released to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It focuses on discovering and also establishing little molecule medication candidates to deal with cancer cells. The Firm‘s products under different phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research experts also just recently discussed the business. Noble Financial reissued a “get” ranking as well as provided a $11.00 price purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and established a “purchase” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving ordinary rate of $2.90 and also a two-hundred day relocating ordinary price of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also a negative internet margin of 8,294.27%. The firm had earnings of $0.06 million throughout the quarter, contrasted to the agreement price quote of $0.06 million. Throughout the exact same quarter in the previous year, the firm published ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will upload -1.18 EPS for the existing year.

A variety of hedge funds have lately bought and sold shares of ONTX. GSA Funding Allies LLP bought a new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Resources Monitoring LP purchased a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a brand-new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional investors own 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the identification and also advancement of oncology therapeutics. It focuses on discovering and establishing small particle medicine prospects to treat cancer. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more information concerning research offerings from Zacks Investment Research, visit Zacks.com.

This instantaneous information alert was created by narrative science modern technology and economic information from Market in order to give viewers with the fastest and most precise reporting. This tale was examined by Market’s editorial group prior to magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?

Before you consider Onconova Therapeutics, you’ll want to hear this.

Market monitors Wall Street’s premier and ideal doing research experts as well as the stocks they recommend to their clients each day. Market has determined the 5 stocks that top experts are silently murmuring to their customers to buy currently before the wider market catches on … and also Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics currently has a “Buy” rating amongst experts, premier experts believe these 5 stocks are much better buys.

Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research